<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899649</url>
  </required_header>
  <id_info>
    <org_study_id>2019-ONC-02</org_study_id>
    <nct_id>NCT03899649</nct_id>
  </id_info>
  <brief_title>A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiodynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiodynamics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, observational study will evaluate the effectiveness and safety of the
      NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3
      PC). Eligible patients will be recruited over a 36-month period and participating
      institutions will enroll and provide data on consecutive patients that meet inclusion and
      exclusion criteria. Each patient will be followed up for the duration of the study or until
      death. The study will include two (2) cohorts: patients who received standard of care (SOC)
      and received irreversible electroporation (IRE) [IRE cohort], and patients who were treated
      with SOC and did not receive IRE [SOC cohort].
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time (in months) from time of enrollment to the date of death for any reason, assessed up to 24 months.</time_frame>
    <description>To evaluate the effectiveness of the NanoKnife System when used for the ablation of Stage 3 PC in real world treatment settings, by testing the hypothesis that IRE with the NanoKnife System improves overall survival (OS)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">532</enrollment>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>IRE Cohort</arm_group_label>
    <description>Patients who received SOC and received IRE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC Cohort</arm_group_label>
    <description>Patients who received SOC and did not receive IRE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Standard of Care treatment</description>
    <arm_group_label>IRE Cohort</arm_group_label>
    <arm_group_label>SOC Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NanoKnife System</intervention_name>
    <description>Irreversible Electroporation</description>
    <arm_group_label>IRE Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cytologically or pathologically confirmed Stage 3 PC who are treated, in
        real-world treatment settings and as part of routine clinical practice, with the NanoKnife
        System (at least 266 patients) for the ablation of their tumor in addition to SOC (IRE
        cohort), or with SOC only (at least 266 patients) (SOC cohort). Patients will be enrolled
        after completing the initial 3-month treatment per SOC for Stage 3 PC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provisions of signed and dated informed consent form

          2. Patient is 18 years of age and older

          3. Patient has a diagnosis of Stage 3 PC cytologically or pathologically confirmed per
             American Joint Committee on Cancer (AJCC) staging criteria

          4. Patient has a tumor evaluated as Stage 3 according to National Comprehensive Cancer
             Network (NCCN) guidelines, based on radiographic imaging or exploratory surgery

          5. Maximum axial and anterior to posterior tumor dimension of â‰¤3.5cm after SOC

          6. Patient has received 3 months of SOC per each participating institution's guidelines

          7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          8. Patient has an American Society of Anesthesiologists (ASA) classification of physical
             health status of 1 or 2.

          9. Patients at IRE sites who are deemed eligible for IRE and receive ablation using the
             NanoKnife System

         10. Patient shows no evidence of disease progression based on NCCN guidelines after
             completing three (3) months of SOC

        Exclusion Criteria:

          1. Participation in an interventional trial for pancreatic cancer during the study data
             collection period

          2. Pregnant or lactating patients or male or female patients of reproductive potential
             who are not willing to employ highly effective birth control from screening to 6
             months after the last dose of chemotherapy

          3. Patients who are unable to tolerate general anesthetic with full skeletal muscle
             blockade

          4. Patients with the presence of implanted cardiac pacemakers, defibrillators, electronic
             devices or implanted devices with metal parts in the thoracic cavity at the time of
             IRE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alicia Conway</last_name>
    <phone>5086587990</phone>
    <phone_ext>7939</phone_ext>
    <email>aconway@angiodynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Garcia</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center, UC San Diego Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shakeela Dad</last_name>
    </contact>
    <investigator>
      <last_name>Rebekah White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Wong, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Montoya</last_name>
    </contact>
    <investigator>
      <last_name>Shree Venkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Cue Barroso</last_name>
    </contact>
    <investigator>
      <last_name>Govindarajan Narayanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Healthcare System</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Jones</last_name>
    </contact>
    <investigator>
      <last_name>Debashish Bose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Tran</last_name>
    </contact>
    <investigator>
      <last_name>Vic Velanovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellstar Medical Group</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Holtzclaw</last_name>
    </contact>
    <investigator>
      <last_name>Sartaj Sanghera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Community Hospital</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Zwicky</last_name>
    </contact>
    <investigator>
      <last_name>Malcolm M Bilimoria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Healey</last_name>
    </contact>
    <investigator>
      <last_name>Robert Martin, MD, PhD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Petty</last_name>
    </contact>
    <investigator>
      <last_name>Chet Hammill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soroya Sanchez Molero</last_name>
    </contact>
    <investigator>
      <last_name>Cataldo Doria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital, Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Flores</last_name>
    </contact>
    <investigator>
      <last_name>Michael Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiral Amin</last_name>
    </contact>
    <investigator>
      <last_name>David Iannitti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Pessin</last_name>
    </contact>
    <investigator>
      <last_name>Darius Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misbah Shabbir</last_name>
    </contact>
    <investigator>
      <last_name>Patricio Polanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Hospital</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Baker</last_name>
    </contact>
    <investigator>
      <last_name>Steven Curley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Alexandria Hospital</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Papadouris</last_name>
    </contact>
    <investigator>
      <last_name>Dimitrios Papadouris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas Cancer</keyword>
  <keyword>Pancreatic Adenocarcinoma</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Advanced Pancreatic Cancer</keyword>
  <keyword>Carcinoma, Pancreatic Ductal</keyword>
  <keyword>Locally Advanced Pancreatic Cancer</keyword>
  <keyword>Cancer of Pancreas</keyword>
  <keyword>Pancreatic Tumor</keyword>
  <keyword>Pancreatic Carcinoma</keyword>
  <keyword>Unresectable Pancreatic Cancer</keyword>
  <keyword>LAPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

